Form 10-K ____________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) _________________________ ...

Pulse Biosciences (Nasdaq : PLSE) March 2020 Forward-looking statements This presentation and accompanying oral presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of March 3, 2020 including, among others, statements regarding Pulse Biosciences' future business plans, products, commercial applications, clinical trials, regulatory processes and pathways, markets for its technologies, and other future events. You should not place undue reliance on forward-looking state ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Brian Dow - SVP & CFO Darrin Uecker - President & CEO Ed Ebbers - EVP & GM, Dermatology Conference Call Participants Arthur He - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences' Third Quarter 2019 Investor and Analyst Update Conference Call. As a reminder, this conference call is being recorded. I'd now like to turn the conference over to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) Pulse Bios ...

Pulse Biosciences, Inc(NASDAQ:PLSE) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Executive Vice President and General Manager of Dermatology Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences' Second Quarter 2019 Earnings Conference Call. [Operat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Pulse Bioscienc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Pulse Bioscien ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2019 Earnings Conference Call April 30, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Vice President and General Manager-Dermatology Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good day, ladies and gentlemen and welcome to the Pulse Biosciences First Quarter 2019 Investor and Analyst Call. At this time, all particip ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Pulse Biosciences | | | | | electromedicine company bringing to market their CellFX™ System, utilizing groundbreaking Nano-Pulse Stimulation TM (NPS) technology | | | | | | | | | | | | | 1 Forward-look ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...